Skip to main content
Clinical Trials/NCT03858335
NCT03858335
Completed
Not Applicable

Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy

Samsung Medical Center1 site in 1 country32 target enrollmentSeptember 14, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cerebral Palsy Spastic Hemiplegic
Sponsor
Samsung Medical Center
Enrollment
32
Locations
1
Primary Endpoint
Change From Baseline Accelerometers_Vector Magnitude Average Counts(VMA) at Post Test
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study evaluates the therapeutic effects of constraint-induced movement therapy on infants and children with hemiplegic cerebral palsy. Half of the participants will receive CIMT (constraint-induced movement therapy) and others will not.

Detailed Description

This study evaluates the therapeutic effects of constraint-induced movement therapy on infants and children with hemiplegic cerebral palsy. Half of the participants will receive CIMT (constraint-induced movement therapy) and others will not. Participants will be randomly assigned to either CIMT group or control group. Children of the CIMT group will wear forearm splint 24 hours for 3 weeks to inhibit use of the unaffected arm.

Registry
clinicaltrials.gov
Start Date
September 14, 2015
End Date
September 28, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jeong Yi Kwon

Professor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

  • spastic hemiplegic cerebral palsy patients
  • 7\~36 months old

Exclusion Criteria

  • cognitive impairment severe enough to make participation impossible
  • uncontrolled epilepsy
  • visual or hearing impairment
  • musculoskeletal disorders

Outcomes

Primary Outcomes

Change From Baseline Accelerometers_Vector Magnitude Average Counts(VMA) at Post Test

Time Frame: baseline and 4 weeks

To evaluate the upper limb use in the real-world, participants wore two accelerometers (one on each wrist). Three variables were measured using accelerometers: vector magnitude average counts (VMA), percent of time in moderate to vigorous physical activity (% MVPA), and use ratio (UR). VMA refers to the magnitude of the resulting vector that forms when combining the sampled acceleration from all three axes.

Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test

Time Frame: baseline and 4 weeks

The PMAL was derived from the Motor Activity Log, which is used as an assessment tool in adults who participated CIMT, to measure changes in upper extremity use in real life. This parental assessment tool rates the use of the children's affected upper extremities in daily activities. Twenty-two arm-hand functional tasks that are typical for children aged 7 months to 8 years (e.g., taking off socks or shoes, holding a cup) were assessed and collected as a systemic data. The test has two components: (1) how often (PMAL HO) and (2) how well (PMAL HW). Parents rate PMAL HO on a 6-point scale from 0 (not at all) to 5 (all the time) and PMAL HW from 0 (does not use) to 5 (same as the unaffected arm). This tool has a high test-retest reliability (r=0.94; P\<0.01) and a high internal consistency (Cronbach's α=0.88 to 0.95).

Secondary Outcomes

  • Change From Baseline Peabody Developmental Motor Scales-2 (PDMS-2) at Post Test(baseline and 4 weeks)
  • Change From Baseline Accelerometers_% Moderate to Vigorous Physical Activity(MVPA) at Post Test(baseline and 4 weeks)
  • Change From Baseline Accelerometers_Use Ratio at Post Test(baseline and 4 weeks)
  • Change From Baseline Gross Motor Function Measure (GMFM) at Post Test(baseline and 4 weeks)
  • Change From Baseline Pediatric Evaluation of Disability Inventory (PEDI) at Post Test(baseline and 4 weeks)

Study Sites (1)

Loading locations...

Similar Trials